This trial is testing a new drug, E-602, to see if it is safe and effective when used alone or with another drug, pembrolizumab.
7 Primary · 10 Secondary · Reporting Duration: 16 Months
Experimental Treatment
273 Total Participants · 4 Treatment Groups
Primary Treatment: E-602 · No Placebo Group · Phase 1 & 2
Age 18+ · All Participants · 6 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: